TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28536126

Group type: EXPERIMENTAL
Intervention: Highest intake of total sugars (median 137 g/d)
Number of subjects: 251261

Group type: EXPERIMENTAL
Intervention: Highest intake of fructose (median 35.2 g/d)
Number of subjects: 251261

Group type: EXPERIMENTAL
Intervention: Highest intake of sucrose (median 78 g/d)
Number of subjects: 251261

Group type: COMPARATOR
Intervention: Lowest intake of total sugars (median 65 g/d)
Number of subjects: 251261

Group type: COMPARATOR
Intervention: Lowest intake of fructose (median 9.7 g/d)
Number of subjects: 251261

Group type: COMPARATOR
Intervention: Lowest intake of sucrose (median 25.8 g/d)
Number of subjects: 251261
Study: 28536493

Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin
Number of subjects: 564

Group type: COMPARATOR
Intervention: S-1 alone
Number of subjects: 564
Study: 28536944

Group type: EXPERIMENTAL
Intervention: Transcutaneous partial pressure of oxygen (PtcO2) monitoring
Number of subjects: 34
Study: 28537061

Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg QD plus lamivudine 300 mg QD
Number of subjects: 20
Study: 28538136

Group type: EXPERIMENTAL
Intervention: Loss-of-function variants in ANGPTL3
Number of subjects: 58335

Group type: EXPERIMENTAL
Intervention: Evinacumab (human monoclonal antibody)
Number of subjects: 58335

Group type: COMPARATOR
Intervention: Control antibody
Number of subjects: 58335
Study: 28538984

Group type: EXPERIMENTAL
Intervention: Medical claims identified events
Number of subjects: 12365

Group type: COMPARATOR
Intervention: Physician adjudicated events
Number of subjects: 12365
Study: 28539464

Group type: EXPERIMENTAL
Intervention: Reparixin in combination with Weekly Paclitaxel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly Paclitaxel
Number of subjects: 0
Study: 28540640

Group type: EXPERIMENTAL
Intervention: Abemaciclib, doses ranging from 50 to 225 mg every 24 hours and 75 to 275 mg every 12 hours
Number of subjects: 224
Study: 28541060

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 74
Study: 28541071

Group type: EXPERIMENTAL
Intervention: Social norm message posters during the intervention phase
Number of subjects: 3
Study: 28542316

Group type: EXPERIMENTAL
Intervention: Antithrombotics resumed until discharge
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Presence of AF
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Non-reinstitution of aspirin until discharge
Number of subjects: 366
Study: 28542350

Group type: EXPERIMENTAL
Intervention: T0001
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab and infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0
Study: 28543053

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily and weight-based ribavirin twice daily for 12 (genotype 2) or 24 (genotype 3) weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sofosbuvir and ribavirin
Number of subjects: 52
Study: 28544782

Group type: EXPERIMENTAL
Intervention: Amphilimus sirolimus-eluting stents (A-SES)
Number of subjects: 1532

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents (ZES)
Number of subjects: 1532
Study: 28544822

Group type: EXPERIMENTAL
Intervention: Tight Control (TC) of inflammation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care (Control)
Number of subjects: 0
Study: 28544991

Group type: EXPERIMENTAL
Intervention: Neighborhood social environment attributes (collective efficacy and perceived crime)
Number of subjects: 6161

Group type: EXPERIMENTAL
Intervention: Higher levels of economic development
Number of subjects: 6161

Group type: EXPERIMENTAL
Intervention: Lower levels of economic development
Number of subjects: 6161
Study: 28545097

Group type: EXPERIMENTAL
Intervention: Integrated model incorporating clinical risk factors and proteomic molecular markers
Number of subjects: 222

Group type: COMPARATOR
Intervention: Clinical risk factors
Number of subjects: 222

Group type: COMPARATOR
Intervention: Proteomic molecular markers
Number of subjects: 222
Study: 28545535

Group type: EXPERIMENTAL
Intervention: Feedback with action implementation toolbox
Number of subjects: 0

Group type: COMPARATOR
Intervention: Feedback without action implementation toolbox
Number of subjects: 0
Study: 28545546

Group type: EXPERIMENTAL
Intervention: Emulsified milk fat (40g)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Unemulsified milk fat (40g)
Number of subjects: 16
Study: 28545575

Group type: EXPERIMENTAL
Intervention: Treadmill exercise testing
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Holter-accelerometer recording
Number of subjects: 40
Study: 28545923

Group type: EXPERIMENTAL
Intervention: FSME-IMMUN 0.5mL
Number of subjects: 315
Study: 28546135

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (ifosfamide and doxorubicin) with 5 days of hypofractionated radiotherapy (25 Gy in 5 fractions) during the second cycle of doxorubicin.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (ifosfamide and doxorubicin) with hypofractionated RT.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypofractionated RT combined with chemotherapy.
Number of subjects: 0
Study: 28546272

Group type: EXPERIMENTAL
Intervention: Hyperoxia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28546279

Group type: EXPERIMENTAL
Intervention: Residual pulmonary obstruction detected through perfusion lung scanning after 6 months.
Number of subjects: 647

Group type: COMPARATOR
Intervention: No residual pulmonary obstruction (control group).
Number of subjects: 647
Study: 28546463

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day plus Prednisone 5 mg b.i.d.
Number of subjects: 8
Study: 28546581

Group type: EXPERIMENTAL
Intervention: Panobinostat (PAN) 30 mg plus Azacitidine (AZA) 75 mg/m²
Number of subjects: 113

Group type: COMPARATOR
Intervention: Azacitidine (AZA) monotherapy
Number of subjects: 113
Study: 28546877

Group type: EXPERIMENTAL
Intervention: Amino Acid Medical Foods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glycomacropeptide Medical Foods
Number of subjects: 0
Study: 28547132

Group type: EXPERIMENTAL
Intervention: Diabetic participants (n=24)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy age- and sex-matched volunteers (n=24)
Number of subjects: 24
Study: 28547872

Group type: EXPERIMENTAL
Intervention: TAVI procedure
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: High white matter lesion (WML) burden
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Periventricular WML burden
Number of subjects: 119
Study: 28547918

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training plus weight loss (AEX+WL)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Weight loss (WL)
Number of subjects: 104
Study: 28548886

Group type: EXPERIMENTAL
Intervention: Regular compliers (RC) (≥2 PIMT/year)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Erratic compliers (EC) (<2 PIMT/year)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Non-compliers (NC) (no PIMT)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: PIMT compliance
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Mucositis
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: PD, PI, BOP, MR, SUP
Number of subjects: 115
Study: 28549082

Group type: EXPERIMENTAL
Intervention: Propofol infusion in patients with frontal brain tumours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Schnider model
Number of subjects: 40

Group type: COMPARATOR
Intervention: Eleveld volunteer model
Number of subjects: 40

Group type: COMPARATOR
Intervention: Marsh model
Number of subjects: 40

Group type: COMPARATOR
Intervention: Eleveld patient model
Number of subjects: 40
Study: 28549424

Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-based cognitive behavior therapy (ePlus) for 12 weeks
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-based cognitive behavior therapy (ePlus)
Number of subjects: 13
Study: 28549516

Group type: EXPERIMENTAL
Intervention: Baseline BCVA of 20/25 or better
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Baseline BCVA between 20/25 and 20/70
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Baseline BCVA between 20/70 and 20/200
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Baseline BCVA worse than 20/200
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 259
Study: 28549834

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 132
Study: 28550003

Group type: EXPERIMENTAL
Intervention: Integrated mobile health platform with smart card technology
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Smart card acceptability among pregnant women
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Smart card usability by pregnant women and health facilities
Number of subjects: 300
Study: 28550039

Group type: EXPERIMENTAL
Intervention: Ixazomib (4.0 mg, days 1, 8, and 15 of 28-day cycles for up to 12 cycles)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ixazomib (4.0 mg) with oral dexamethasone (40 mg, days 1-4) for patients with less than partial response after 3 cycles
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ixazomib (4.0 mg)
Number of subjects: 27
Study: 28550098

Group type: EXPERIMENTAL
Intervention: Powered exoskeleton driven by a brain-computer interface (BCI) used at home for 12 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Powered exoskeleton driven by a brain-computer interface (BCI)
Number of subjects: 10
Study: 28550192

Group type: EXPERIMENTAL
Intervention: Khorana score
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: PROTECHT score
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: Vienna score
Number of subjects: 876
Study: 28550439

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 103
Study: 28551166

Group type: EXPERIMENTAL
Intervention: 10-2 visual fields
Number of subjects: 775
Study: 28551359

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (2 mg/kg or 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks)
Number of subjects: 97
Study: 28551430

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Exercise training (group training setting)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 28
Study: 28552512

Group type: EXPERIMENTAL
Intervention: PCV13 (0.5ml intramuscularly)
Number of subjects: 49
Study: 28552987

Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1 therapy)
Number of subjects: 29
Study: 28554226

Group type: EXPERIMENTAL
Intervention: Multiple-electrode switching system (MESS) radiofrequency ablation (RFA)
Number of subjects: 516
Study: 28554585

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Baseline tricuspid annular plane systolic excursion (TAPSE)
Number of subjects: 79
Study: 28554602

Group type: EXPERIMENTAL
Intervention: Buprenorphine medication-assisted treatment (B-MAT)
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Attitudes toward sharing buprenorphine
Number of subjects: 476

Group type: EXPERIMENTAL
Intervention: Attitudes toward selling buprenorphine
Number of subjects: 476
Study: 28554656

Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy (CCE)
Number of subjects: 177
Study: 28554917

Group type: EXPERIMENTAL
Intervention: Onco-TreC 2.0 remote monitoring system
Number of subjects: 80
Study: 28554936

Group type: EXPERIMENTAL
Intervention: Faecal calgranulin C (S100A12) stool test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Faecal calprotectin (FC) stool test
Number of subjects: 0
Study: 28554935

Group type: EXPERIMENTAL
Intervention: Air-Test
Number of subjects: 350
Study: 28555039

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acids (PUFA) supplementation, dosage and duration not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fatty acid desaturase activities, specific activities not specified
Number of subjects: 0
Study: 28555339

Group type: EXPERIMENTAL
Intervention: iBGStar
Number of subjects: 100

Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG) with Accu-Chek Nano
Number of subjects: 100
Study: 28555519

Group type: EXPERIMENTAL
Intervention: E/C/F/TDF (switch group)
Number of subjects: 429

Group type: COMPARATOR
Intervention: PI + RTV + TVD (no-switch group)
Number of subjects: 429
Study: 28555533

Group type: EXPERIMENTAL
Intervention: Pulse Amplitude Tonometry (PAT) in patients with diabetic nephropathy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pulse Amplitude Tonometry (PAT) in patients with heart failure with preserved ejection fraction (HFpEF)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pulse Amplitude Tonometry (PAT) in patients with heart failure with reduced ejection fraction (HFrEF)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pulse Amplitude Tonometry (PAT) in patients with arterial hypertension
Number of subjects: 91
Study: 28555565

Group type: EXPERIMENTAL
Intervention: Elevated neural activity and global brain connectivity in the intraparietal sulcus (IPS) during threat exposure.
Number of subjects: 0
Study: 28558079

Group type: EXPERIMENTAL
Intervention: Minimum TpTe interval ≤ 50 ms
Number of subjects: 79

Group type: COMPARATOR
Intervention: Child B
Number of subjects: 79

Group type: COMPARATOR
Intervention: Child C
Number of subjects: 79

Group type: COMPARATOR
Intervention: Child A
Number of subjects: 79
Study: 28558663

Group type: EXPERIMENTAL
Intervention: Mailed fecal tests (at least two rounds)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CRC screening blood test (potential option)
Number of subjects: 41
Study: 28558737

Group type: EXPERIMENTAL
Intervention: Active case finding (ACF) strategies for TB, including clinic-based strategies (screening all patients regardless of visit purpose)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Household outreach and incentive-based strategies
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Proactive case finding strategies
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Content analysis of interviews and focus groups
Number of subjects: 27
Study: 28558800

Group type: EXPERIMENTAL
Intervention: Maternity waiting homes (MWH) rated medium or high quality
Number of subjects: 17200

Group type: EXPERIMENTAL
Intervention: Facilities with MWH or space for pregnant waiting mothers
Number of subjects: 17200

Group type: COMPARATOR
Intervention: Facilities without MWH or accommodations
Number of subjects: 17200
Study: 28558812

Group type: EXPERIMENTAL
Intervention: Onsite antenatal syphilis screening intervention including onsite training, provision of supplies and medicines, quality control and supervision.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Point-of-care test for syphilis.
Number of subjects: 7
Study: 28559019

Group type: EXPERIMENTAL
Intervention: Dasatinib and cetuximab
Number of subjects: 13
Study: 28559225

Group type: EXPERIMENTAL
Intervention: Video-based counseling combined with home-based HIV testing
Number of subjects: 400

Group type: COMPARATOR
Intervention: Home-based HIV self-testing kits (control arm)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Home-based HIV self-testing kits with video-based counseling (experimental arm)
Number of subjects: 400
Study: 28559458

Group type: EXPERIMENTAL
Intervention: Team 2 (1 NP, 3 GPs)
Number of subjects: 9503

Group type: EXPERIMENTAL
Intervention: Team 3 (2 NPs, 2 GPs)
Number of subjects: 9503

Group type: COMPARATOR
Intervention: Team 1 (4 GPs)
Number of subjects: 9503
Study: 28559537

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT)
Number of subjects: 0
Study: 28560656

Group type: EXPERIMENTAL
Intervention: Greater social well-being (SWB) assessed with the social/family well-being subscale of the FACT-B
Number of subjects: 50

Group type: COMPARATOR
Intervention: Emotional well-being, physical well-being, and functional well-being
Number of subjects: 50
Study: 28562108

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Histamine-2-receptor antagonists (H2RAs)
Number of subjects: 0
Study: 28564715

Group type: EXPERIMENTAL
Intervention: Two-stage endoscopic mucosal resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-session approach
Number of subjects: 0
Study: 28566263

Group type: COMPARATOR
Intervention: Control group (Treatment as usual with the endocrinologist and the nurse + Bodyguard2)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PRECIOUS system (Bodyguard2 + PRECIOUS app)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PRECIOUS system (Bodyguard2 + PRECIOUS app + Motivational Interviewing)
Number of subjects: 31
Study: 28566290

Group type: EXPERIMENTAL
Intervention: Boston Scientific Lotus valve
Number of subjects: 537

Group type: COMPARATOR
Intervention: Edwards Sapien 3 valve
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Boston Scientific Lotus valve and Edwards Sapien 3 valve
Number of subjects: 537
Study: 28566292

Group type: EXPERIMENTAL
Intervention: Permanent right internal mammary artery device closure
Number of subjects: 50
Study: 28566335

Group type: EXPERIMENTAL
Intervention: MenB-FHbp vaccine
Number of subjects: 17
Study: 28566657

Group type: EXPERIMENTAL
Intervention: Leadless intracardiac transcatheter pacing system in Japanese patients
Number of subjects: 38
Study: 28566948

Group type: EXPERIMENTAL
Intervention: NMDAR-Ab from ASD patient serum
Number of subjects: 1

Group type: COMPARATOR
Intervention: NMDAR-Ab from seropositive healthy subject
Number of subjects: 1
Study: 28567369

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral agents (DAAs) treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study: 28567688

Group type: EXPERIMENTAL
Intervention: Upper-airway stimulation (UAS) device (Inspire Medical Systems)
Number of subjects: 26
Study: 28568564

Group type: EXPERIMENTAL
Intervention: Absorb BVS using PSP-technique
Number of subjects: 319
Study: 28569047

Group type: EXPERIMENTAL
Intervention: Alglucerase/imiglucerase enzyme replacement therapy (ERT)
Number of subjects: 0
Study: 28569141

Group type: EXPERIMENTAL
Intervention: Group B Streptococcus (GBS) cases detected in selected hospitals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GBS isolates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antimicrobial susceptibility testing
Number of subjects: 0
Study: 28569206

Group type: EXPERIMENTAL
Intervention: 3-direct-acting-antiviral (DAA) regimen combining simeprevir (SMV), TMC647055/ritonavir (RTV), and JNJ-56914845
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2-DAA regimen SMV + TMC647055/RTV with or without ribavirin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3-DAA regimen
Number of subjects: 90
Study: 28569213

Group type: EXPERIMENTAL
Intervention: Mansoura-VV uterine compression sutures
Number of subjects: 108
Study: 28569222

Group type: EXPERIMENTAL
Intervention: Positive family history (PFH) of ankylosing spondylitis (AS)
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: Positive family history (PFH) of acute anterior uveitis (AAU)
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: Positive family history (PFH) of reactive arthritis (ReA)
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: Positive family history (PFH) of inflammatory bowel disease (IBD)
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: Positive family history (PFH) of psoriasis
Number of subjects: 1085
Study: 28569603

Group type: EXPERIMENTAL
Intervention: Flexicult™ SSI-Urinary Kit or ID Flexicult™ (POC urine culture tests)
Number of subjects: 341
Study: 28569683

Group type: EXPERIMENTAL
Intervention: Qualitative assessment through key stakeholder focus groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative assessment involving height/weight measurement and dietary recalls
Number of subjects: 0
Study: 28570698

Group type: EXPERIMENTAL
Intervention: CAA-related lobar ICH
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Deep ICH
Number of subjects: 77

Group type: COMPARATOR
Intervention: MCI-AD
Number of subjects: 77

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 77
Study: 28570742

Group type: EXPERIMENTAL
Intervention: Conformal radiation therapy (RT) individualized to a fixed risk of RT-induced lung toxicity (RILT) and adaptively escalated to the residual tumor defined on midtreatment FDG-PET up to a total dose of 86 Gy in 30 daily fractions, with concurrent weekly carboplatin plus paclitaxel.
Number of subjects: 42
Study: 28570796

Group type: EXPERIMENTAL
Intervention: SRI-exposed group (women with a mood disorder taking SRI)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Mood Disorder group (women with depression or bipolar disorder not taking psychotropic medications)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Comparison group (women not taking psychotropics and no major mood disorder)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Preterm newborns
Number of subjects: 214
Study: 28571635

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 179810

Group type: EXPERIMENTAL
Intervention: β-blockers in ST-segment elevation myocardial infarction
Number of subjects: 179810

Group type: EXPERIMENTAL
Intervention: β-blockers in non-ST-segment elevation myocardial infarction
Number of subjects: 179810

Group type: COMPARATOR
Intervention: No β-blockers (Control)
Number of subjects: 179810
Study: 28571639

Group type: EXPERIMENTAL
Intervention: Fontan procedure
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Exercise performance
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Ejection fraction
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Pediatric Quality of Life Inventory physical summary score
Number of subjects: 373
Study: 28572079

Group type: EXPERIMENTAL
Intervention: WelTel SMS text-message intervention
Number of subjects: 80
Study: 28572163

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 514
Study: 28574652

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg administered once daily
Number of subjects: 20
Study: 28574663

Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived regenerative cells (ADRC)
Number of subjects: 6
Study: 28575201

Group type: EXPERIMENTAL
Intervention: PHIV women
Number of subjects: 2270

Group type: EXPERIMENTAL
Intervention: PHIV women aged 23-30 years
Number of subjects: 2270

Group type: COMPARATOR
Intervention: NPHIV women
Number of subjects: 2270